Status:
COMPLETED
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Lead Sponsor:
Galderma R&D
Conditions:
Papulopustular Rosacea
Eligibility:
All Genders
25-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
Eligibility Criteria
Inclusion
- Men and women
- 25-70 years
- Diagnosis of papulopustular rosacea
- Eligible for Oracea treatment
Exclusion
- Allergies to components of investigational product and/or hypersensitivity to tetracyclines
- Taken systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit
- Used topical rosacea treatment within 30 days prior to baseline visit
- Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an opthalmologist
- Previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics
- Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to baseline and/or who forsee unprotected and intense/excessive UV exposure during the course of the study
- Have planned surgical procedures during the course of the study
- Have used tetracycline antibiotics within 30 days prior to baseline visit or during study
- At risk in terms of precautions, warnings, and contraindications
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01872715
Start Date
March 1 2013
End Date
June 1 2013
Last Update
August 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stephens & Associates Dallas Research Center
Carrollton, Texas, United States, 75006